

General Assignment

Between

FARES, Wassim (hereinafter referred to as "Assignor")

AND

Janssen Research & Development, LLC, having its place of business at 920 US Route 202, PO Box 300, Raritan NJ 08869, USA (hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

**"PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PULMONARY VASCULAR DISEASE
AND/OR CARDIAC DYSFUNCTION IN FONTAN-PALLIATED PATIENTS"**

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee. The Assignor is co-inventor of the Invention,

for which on the 25th day of November 2020, International patent application no. PCT/EP2020/083289 was filed at European Patent Office.

WHEREAS, the conditions under which said Invention was made are such that as defined in the contract as an employee of Assignee, the Assignor automatically entitles Assignee to the entire right, title and interest to said Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt of which from the Assignee is hereby acknowledged, the Assignor for the avoidance of doubt hereby assigns and transfers to the Assignee his entire right, title and interest, including the right to claim priority of a priority application for the Invention, in and to said Invention and improvements thereof, which may be disclosed in a patent application and in and to said patent application, and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.


The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this Assignment, and the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

The Assignor further agrees to make, execute and deliver to the Assignee upon request, any and all papers, documents, declarations, affidavits, or other instruments that may be necessary in the prosecution of any application or applications for the Invention and improvements thereof, including all provisionals, substitutions, divisions, and continuations thereof, or for Letter Patents, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, and to assist the Assignee in every way as may be requested in protecting said Invention. The Assignor acknowledges that this obligation includes the duty to execute, in a timely manner, any Declaration and Power of Attorney that may be necessary in the prosecution of applications relating to said Invention in the United States or elsewhere.

ACT6004

The Assignor agrees that this general assignment is effective from the 26th day of November 2019.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

Wassim Fares 

FARES, Wassim

Signature Date: Dec 14th, 2020

Authorized Signatory

For Janssen Research & Development LLC

Signature Date:

General Assignment**Between****FARES, Wassim** (hereinafter referred to as "Assignor")**AND****Janssen Research & Development, LLC**, having its place of business at 920 US Route 202, PO Box 300, Raritan NJ 08869, USA (hereinafter referred to as "Assignee")

WHEREAS at the time the invention of

**"PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PULMONARY VASCULAR DISEASE
AND/OR CARDIAC DYSFUNCTION IN FONTAN-PALLIATED PATIENTS"**

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee. The Assignor is co-inventor of the Invention,

for which on the 25th day of November 2020, International patent application no. PCT/EP2020/083289 was filed at European Patent Office.

WHEREAS, the conditions under which said Invention was made are such that as defined in the contract as an employee of Assignee, the Assignor automatically entitles Assignee to the entire right, title and interest to said Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt of which from the Assignee is hereby acknowledged, the Assignor for the avoidance of doubt hereby assigns and transfers to the Assignee his entire right, title and interest, including the right to claim priority of a priority application for the Invention, in and to said Invention and improvements thereof, which may be disclosed in a patent application and in and to said patent application, and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.


The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this Assignment, and the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

The Assignor further agrees to make, execute and deliver to the Assignee upon request, any and all papers, documents, declarations, affidavits, or other instruments that may be necessary in the prosecution of any application or applications for the Invention and improvements thereof, including all provisionals, substitutions, divisions, and continuations thereof, or for Letter Patents, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, and to assist the Assignee in every way as may be requested in protecting said Invention. The Assignor acknowledges that this obligation includes the duty to execute, in a timely manner, any Declaration and Power of Attorney that may be necessary in the prosecution of applications relating to said Invention in the United States or elsewhere.

The Assignor agrees that this general assignment is effective from the 26th day of November 2019.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

FARES, Wassim
Signature Date:



Authorized Signatory
For Janssen Research & Development LLC
Signature Date:

15-FEB-2021

General Assignment

Between

CSONKA, Dénes (hereinafter referred to as "Assignor")

AND

Actelion Pharmaceuticals Ltd having its place of business at Gewerbstrasse 16, 4123 Allschwil, Switzerland (hereinafter referred to as "Assignee"),

WHEREAS at the time the invention of

"PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PULMONARY VASCULAR DISEASE AND/OR CARDIAC DYSFUNCTION IN FONTAN-PALLIATED PATIENTS

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee. The Assignor is co-inventor of the Invention,

for which on the 25th day of November 2020, International patent application no. PCT/EP2020/083289 was filed at European Patent Office.

WHEREAS, the conditions under which said Invention was made are such that as defined in the contract as an employee of Assignee, the Assignor automatically entitles Assignee to the entire right, title and interest to said Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt of which from the Assignee is hereby acknowledged, the Assignor for the avoidance of doubt hereby assigns and transfers to the Assignee his entire right, title and interest, including the right to claim priority of a priority application for the Invention, in and to said Invention and improvements thereof, which may be disclosed in a patent application and in and to said patent application, and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this Assignment, and the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

The Assignor further agrees to make, execute and deliver to the Assignee upon request, any and all papers, documents, declarations, affidavits, or other instruments that may be necessary in the prosecution of any application or applications for the Invention and improvements thereof, including all provisionals, substitutions, divisions, and continuations thereof, or for Letter Patents, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, and to assist the Assignee in every way as may be requested in protecting said Invention. The Assignor acknowledges that this obligation includes the duty to execute, in a timely manner, any Declaration and Power of Attorney that may be necessary in the prosecution of applications relating to said Invention in the United States or elsewhere.

The Assignor agrees that this general assignment is effective from the 26th day of November 2019.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

CSONKA, Dénes
Signature Date:

CS
14 DEC 2020



Authorized Signatory
For Actelion Pharmaceuticals Ltd
Signature Date: 18.12.2020

Nathalie Gutenstein
Legal Director

Marc Streule
Legal Director

General Assignment

Between

HOOGKAMER, Hans (hereinafter referred to as "Assignor")

AND

Actelion Pharmaceuticals Ltd having its place of business at Gewerbstrasse 16, 4123 Allschwil, Switzerland (hereinafter referred to as "Assignee"),

WHEREAS at the time the invention of

"PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PULMONARY VASCULAR DISEASE AND/OR CARDIAC DYSFUNCTION IN FONTAN-PALLIATED PATIENTS

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee. The Assignor is co-inventor of the Invention,

for which on the 25th day of November 2020, International patent application no. PCT/EP2020/083289 was filed at European Patent Office.

WHEREAS, the conditions under which said Invention was made are such that as defined in the contract as an employee of Assignee, the Assignor automatically entitles Assignee to the entire right, title and interest to said Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign.


NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt of which from the Assignee is hereby acknowledged, the Assignor for the avoidance of doubt hereby assigns and transfers to the Assignee his entire right, title and interest, including the right to claim priority of a priority application for the Invention, in and to said Invention and improvements thereof, which may be disclosed in a patent application and in and to said patent application, and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this Assignment, and the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

The Assignor further agrees to make, execute and deliver to the Assignee upon request, any and all papers, documents, declarations, affidavits, or other instruments that may be necessary in the prosecution of any application or applications for the Invention and improvements thereof, including all provisionals, substitutions, divisions, and continuations thereof, or for Letter Patents, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, and to assist the Assignee in every way as may be requested in protecting said Invention. The Assignor acknowledges that this obligation includes the duty to execute, in a timely manner, any Declaration and Power of Attorney that may be necessary in the prosecution of applications relating to said Invention in the United States or elsewhere.

The Assignor agrees that this general assignment is effective from the 26th day of November 2019.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.



HOOGLKAMER, HANS

GSONKA, Dénes
Signature Date:

4.12.2020


Authorized Signatory
For Actelion Pharmaceuticals Ltd
Signature Date: 18.12.2020

Nathalie Gutenstein
Legal Director


Marc Streule
Legal Director

General Assignment**Between****TORFS, Koen** (hereinafter referred to as "Assignor")**AND****Janssen Pharmaceutica NV**, Turnhoutseweg 30, having its place of business at 2340 Beerse, Belgium (hereinafter referred to as "Assignee"),

WHEREAS at the time the invention of

"PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PULMONARY VASCULAR DISEASE AND/OR CARDIAC DYSFUNCTION IN FONTAN-PALLIATED PATIENTS"

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee. The Assignor is co-inventor of the Invention,

for which on the 25th day of November 2020, International patent application no. PCT/EP2020/083289 was filed at European Patent Office.

WHEREAS, the conditions under which said Invention was made are such that as defined in the contract as an employee of Assignee, the Assignor automatically entitles Assignee to the entire right, title and interest to said Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt of which from the Assignee is hereby acknowledged, the Assignor for the avoidance of doubt hereby assigns and transfers to the Assignee his entire right, title and interest, including the right to claim priority of a priority application for the Invention, in and to said Invention and improvements thereof, which may be disclosed in a patent application and in and to said patent application, and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.


The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this Assignment, and the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

The Assignor further agrees to make, execute and deliver to the Assignee upon request, any and all papers, documents, declarations, affidavits, or other instruments that may be necessary in the prosecution of any application or applications for the Invention and improvements thereof, including all provisionals, substitutions, divisions, and continuations thereof, or for Letter Patents, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, and to assist the Assignee in every way as may be requested in protecting said Invention. The Assignor acknowledges that this obligation includes the duty to execute, in a timely manner, any Declaration and Power of Attorney that may be necessary in the prosecution of applications relating to said Invention in the United States or elsewhere.

The Assignor agrees that this general assignment is effective from the 26th day of November 2019.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

TORFS, Koen
Signature Date:

A handwritten signature in black ink, consisting of a large, stylized 'K' followed by a horizontal line.

25.01.2021

Authorized Signatory
For Janssen Pharmaceutica NV
Signature Date:

General Assignment**Between****TORFS, Koen** (hereinafter referred to as "Assignor")**AND**

Janssen Pharmaceutica NV, Turnhoutseweg 30, having its place of business at 2340 Beerse, Belgium (hereinafter referred to as "Assignee"),

WHEREAS at the time the invention of

**"PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PULMONARY VASCULAR DISEASE
AND/OR CARDIAC DYSFUNCTION IN FONTAN-PALLIATED PATIENTS"**

(hereinafter referred to as "Invention") was made, Assignor was an employee of Assignee. The Assignor is co-inventor of the Invention,

for which on the 25th day of November 2020, International patent application no. PCT/EP2020/083289 was filed at European Patent Office.

WHEREAS, the conditions under which said Invention was made are such that as defined in the contract as an employee of Assignee, the Assignor automatically entitles Assignee to the entire right, title and interest to said Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign; and

WHEREAS, the Assignee is desirous of acquiring Assignor's entire right, title and interest in the Invention and improvements thereof, including the right to claim priority of a priority application for the Invention, both domestic and foreign.

NOW, THEREFORE, BE IT KNOWN, that, for good and valuable consideration the receipt of which from the Assignee is hereby acknowledged, the Assignor for the avoidance of doubt hereby assigns and transfers to the Assignee his entire right, title and interest, including the right to claim priority of a priority application for the Invention, in and to said Invention and improvements thereof, which may be disclosed in a patent application and in and to said patent application, and all foreign equivalents thereof, including all provisionals, substitutions, divisions, and continuations thereof, and in and to all Letters Patent, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

The Assignor covenants that the Assignor has the full right and obligation to convey the interest assigned by this Assignment, and the Assignor has not executed and will not execute any agreement in conflict with this Assignment.

The Assignor further agrees to make, execute and deliver to the Assignee upon request, any and all papers, documents, declarations, affidavits, or other instruments that may be necessary in the prosecution of any application or applications for the Invention and improvements thereof, including all provisionals, substitutions, divisions, and continuations thereof, or for Letter Patents, both domestic and foreign, that may be granted for said Invention, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, and to assist the Assignee in every way as may be requested in protecting said Invention. The Assignor acknowledges that this obligation includes the duty to execute, in a timely manner, any Declaration and Power of Attorney that may be necessary in the prosecution of applications relating to said Invention in the United States or elsewhere.

The Assignor agrees that this general assignment is effective from the 26th day of November 2019.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

TORFS, Koen
Signature Date:


Authorized Signatory
For Janssen Pharmaceutica NV
Signature Date: 15 Feb 2021

General Assignment

WHEREAS, **Janssen Pharmaceutica NV** having its place of business at Turnhoutseweg 30, 2340 Beerse, Belgium (hereinafter referred to as "Assignor"), is the owner of certain new and useful inventions relating to

"PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PULMONARY VASCULAR DISEASE AND/OR CARDIAC DYSFUNCTION IN FONTAN-PALLIATED PATIENTS"

for which on the 25th day of November 2020, International Patent Application no. PCT/EP2020/083289 was filed at the European Patent Office.

WHEREAS, **Actelion Pharmaceuticals Ltd**, having its place of business at Gewerbestrasse 16, 4123 Allschwil, Switzerland (hereinafter referred to as "Assignee") is desirous of acquiring Assignors' entire right, title and interest therein, including the right to claim priority thereof,

NOW, THEREFORE, BE IT KNOWN, that in view of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor hereby assigns and transfers, for all countries in the world, to said Assignee its entire right, title and interest, including the right to claim priority, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof, including all substitutions, divisions, and continuations thereof, and in and to all Letters Patent, that may be granted for said inventions, and in and to all extensions, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

And for purpose of obtaining patent protection in any foreign country, the Assignor hereby agrees that, any right, title and interest, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof can be directly assigned by the inventors to the Assignee without explicit confirmation of the Assignor.

The Assignor agrees that this general assignment is effective from the 26th day of November 2019.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

For Janssen Pharmaceutica NV

For Actelion Pharmaceuticals Ltd



 Authorized Signatory
 For Janssen Pharmaceutica NV
 Signature Date :

15 Feb 2021
FRANK DAELEMAN
 VICE PRESIDENT



 Authorized Signatory
 For Actelion Pharmaceuticals Ltd
 Signature Date : 7.4.2021

Eric Ruhlmann
 European Patent Attorney
 Senior Patent Counsel


Dr. Frank Schager
 European Patent Attorney
 Chief Patent Counsel

General Assignment

WHEREAS, **Janssen Research & Development, LLC**, having its place of business at 920 US Route 202, PO Box 300, Raritan NJ 08869, USA (hereinafter referred to as "Assignor"), is the owner of certain new and useful inventions relating to

"PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PULMONARY VASCULAR DISEASE AND/OR CARDIAC DYSFUNCTION IN FONTAN-PALLIATED PATIENTS"

for which on the 25th day of November 2020, International Patent Application no. PCT/EP2020/083289 was filed at the European Patent Office.

WHEREAS, Actelion Pharmaceuticals Ltd, having its place of business at Gewerbestrasse 16, 4123 Allschwil, Switzerland (hereinafter referred to as "Assignee") is desirous of acquiring Assignors' entire right, title and interest therein, including the right to claim priority thereof,

NOW, THEREFORE, BE IT KNOWN, that in view of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor hereby assigns and transfers, for all countries in the world, to said Assignee its entire right, title and interest, including the right to claim priority, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof, including all substitutions, divisions, and continuations thereof, and in and to all Letters Patent, that may be granted for said inventions, and in and to all extensions, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.


And for purpose of obtaining patent protection in any foreign country, the Assignor hereby agrees that, any right, title and interest, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof can be directly assigned by the inventors to the Assignee without explicit confirmation of the Assignor.

The Assignor agrees that this general assignment is effective from the 25th day of January 2019.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

For Janssen Research & Development LLC

For Actelion Pharmaceuticals Ltd


Authorized Signatory
For Janssen Research & Development LLC
Signature Date :
15 - FEB - 2021


Authorized Signatory
For Actelion Pharmaceuticals Ltd
Signature Date : 7 4. 2021

Eric Ruhlmann
European Patent Attorney
Senior Patent Counsel


Dr. Frank Schager
European Patent Attorney
Chief Patent Counsel